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Objectives. This study was performed to determine the degree
and time course over 6 years of cardiomyocyte hypertrophy and
myocardial fibrosis of the cardiac allograft in transplanted pa-
tients.
Background. Diastolic dysfunction and to a certain extent
systolic dysfunction are common cardiac findings after heart
transplantation. The development of posttransplant cardiomyo-
cyte hypertrophy and myocardial fibrosis likely contributes to
these derangements.
Methods. Cardiomyocyte diameter and percent fibrosis were
determined in serial endomyocardial biopsy specimens obtained
from 1 month up to 6 years following heart transplantation in 50
patients. Endomyocardial biopsy specimens from 40 patients with
primary dilated cardiomyopathy and 11 normal subjects were
similarly analyzed for control data. Analyses were performed in a
blinded format using a validated computerized image analysis
system (Optimas 5.2).
Results. Early (1 month) cardiomyocyte enlargement decreased
to the smallest diameter 6 months posttransplant, but thereafter
progressively increased by 10% to 20% over the subsequent 5- to
6-year period. Although not statistically established, principal
stimuli may include a discrepancy in body size (recipient >
donor), coronary allograft vasculopathy and posttransplant sys-
temic hypertension. Percent myocardial fibrosis rose early (1 to 2
months) posttransplant and thereafter remained at the same
modest level of severity.
Conclusions. Cardiomyocyte diameter of the transplanted heart
gradually increases over time, while percent myocardial fibrosis
rises early and remains in a modestly elevated plateau after 2
months posttransplant. These histostructural changes likely con-
tribute to the hemodynamic and cardiac functional alterations
commonly observed posttransplant.
(J Am Coll Cardiol 1998;32:704–10)
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It is generally accepted that cardiac allografts undergo some
cardiomyocyte hypertrophy and myocardial fibrosis after trans-
plantation (1–3). While the specific causes for these changes
have not been definitively established, it is likely that the
histologic alterations contribute to the functional changes of
the transplanted heart, particularly myocardial stiffness, dia-
stolic dysfunction and, to a certain extent, systolic dysfunction
(4–11).
The time course and extent of cardiomyocyte hypertrophy
and interstitial fibrosis in human transplanted hearts have not
been determined. We hypothesized that these histostructural
changes increase in a progressive manner throughout the
posttransplant course. This blinded retrospective study em-
ployed computerized morphometric methodology to analyze
serial endomyocardial biopsies obtained over 6 years from 50
patients with cardiac allografts for the purpose of testing this
hypothesis. Biopsies from 40 patients with dilated cardiomy-
opathy and 11 subjects with normal cardiac function were
analyzed under the same conditions to provide control data for
comparison.
Methods
Study populations. The posttransplant study group repre-
sents all patients who survived 5 years or more after orthotopic
cardiac transplantation at The Ohio State University Medical
Center; these 50 posttransplant patients consist of 35 men and
15 women with a mean (6 1 SD) age of 45 6 10 years (range
12 to 59 years). The pretransplantation cardiac diagnoses were
atherosclerotic heart disease for 22 patients, nonischemic
dilated cardiomyopathy for 26 patients and hypertrophic car-
diomyopathy for 2 patients. All underwent cardiac transplan-
tation at The Ohio State University Medical Center from 1986
to 1991 such that serial endomyocardial biopsy specimens were
available for posttransplant periods $5 years.
The cardiac allograft biopsies used for this study were taken
from the 50 recipients at set intervals following transplanta-
tion; specifically at 1, 2, 4, 6, 9 and 12 months, and every 6
months out to 5 years posttransplant for all 50 patients and out
to 6 years for 30 of them.
Two control groups provided endomyocardial biopsy sam-
ples for comparison. Eleven subjects, 7 men and 4 women with
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a mean age of 33 6 10 (range 17 to 50) years, with no
demonstrable clinical or anatomic (echocardiography) heart
disease served as the normal control group. These subjects
underwent heart biopsy as part of an oncologic, prechemo-
therapy protocol. Forty patients, 21 men and 19 women with a
mean age of 40 6 14 (range 18 to 68) years, afflicted with
primary dilated cardiomyopathy of a duration ranging from 1
month to 8 years served as the dilated cardiomyopathy control
group. All patients of this group underwent diagnostic cardiac
catheterization and echocardiography. Patients with historical,
clinical or laboratory evidence of systemic hypertension, val-
vular disease, occlusive coronary artery disease or other non-
myocardial structural disorders were excluded.
After written informed consent was obtained for each
procedure, four right ventricular-septal endomyocardial bi-
opsy specimens were taken at each biopsy procedure via
standard technique (12) using a disposable Cordis 54 cm,
2.2 mm forceps bioptome. All specimens were placed im-
mediately (, 10 s after forceps closure) in 10% formalin and
subsequently embedded in a single paraffin block. Sections
were sliced 4-mm thick and mounted on glass slides. A slice
taken from the specimen depth of 60% to 70% was then
stained with Masson trichrome for microscopic visualization
and image analysis.
Morphometric analysis. Field sampling by light micros-
copy was used to select the region for analysis. One micro-
scopic field was isolated per biopsy slide as a representation of
that biopsy. The fields were generally taken from the midpor-
tions of the biopsy sample, purposely avoiding areas of inflam-
mation, vasculitis, ischemic change, ischemia-induced fibrous
replacement, crush-distortion artifact and scar tissue from a
prior biopsy. Each field for analysis had to contain predomi-
nately longitudinally sectioned cardiomyocytes. The sampling
fields were digitized to a computer database via a light
microscope (Zeiss, Thornwood, NY) through a 203 objective
lens, coupled to a high resolution color camera (Hitachi model
No. HV-C11, Woodbury, NY) that interfaced with an IBM-
compatible Pentium computer (Everex, Freemont, CA). The
digitized biopsy fields were then magnified 7603 and analyzed
using Optimas 5.2 image analysis software (Optimas Inc.,
Edmonds, WA) (see Fig. 1, panel A). The image analysis
software was calibrated using a stage micrometer (Klarmann
Rulings, Manchester, NH) traceable to the National Institute
of Standards Technology; the mean of 14 measurements was
within 0.06 mm of the stage micrometer standard.
The myocyte diameters within the field were measured
using standard criteria (13). A point-to-point perpendicular
line was placed across the longitudinally cut myocyte at the
level of the nucleus (Fig. 1, B) and this diameter length was
then measured by the computer-imaging software. All of the
longitudinally directed myocytes with a distinct cell border (at
the level of the nucleus) within the sampling field were
measured and averaged to provide the mean cardiomyocyte
diameter. Transverse or oblique cut myocytes were excluded.
Cell width was determined from longitudinally positioned
myocytes to reduce the error of determining such for myocytes
that may not be precisely cut perpendicular to their long axis.
The interstitial fibrosis within the same selected field of
each biopsy was then quantified. The imaging software, pro-
grammed to recognize color and distinct shades, highlighted
pixels of a particular color or shade we specified within the
field. Fibrosis becomes blue with Masson trichrome stain,
Figure 1. A, Region of interest (sampling field) of an endomyocardial
biopsy specimen (Masson trichrome stain). B, Perpendicular measure-
ment lines were placed across sectioned horizontal cardiomyocytes at
the level of midnucleus. The line lengths were measured and averaged
by computer software to provide the mean myocyte diameter of the
biopsy specimen. C, Using the operator’s threshold settings, the
myocardial fibrous tissue was highlighted (blue) and measured by
computer software as percent of myocardial tissue. The white non-
tissue spaces were similarly demarcated, measured and subtracted to
provide a corrected area of true myocardial tissue.
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which the imaging software highlighted within the field (based
on the operator’s threshold settings) and calculated the
amount of area it occupied (Fig. 1, C). The white, nontissue
spaces of the field were recognized (with operator-threshold
settings) by the software and subtracted to provide a corrected
area of total myocardial tissue in the field. The ratio of the area
of fibrotic tissue to total myocardial tissue area (3 100%) was
then calculated to provide a measure of percent fibrosis.
Because the tissue samples were removed by biopsy from
living patients, the methodology does not lend itself to perfu-
sion fixation, analysis of myocardium from multiple transmural
or biventricular sites and other methodological considerations.
Left ventricular biopsies add unacceptable risk. Despite the
inability to employ perfusion fixation, control contracture or
stretch of the cardiomyocytes, sample multiple sites and so
forth, all biopsy specimens were obtained, processed and
analyzed in the very same manner to render reasonable validity
to changes in mean values. Because of methodological differ-
ences, the data of this investigation may not necessarily
correspond closely to those obtained from hearts removed at
necropsy or explanted during surgery (if the data from these
sampling conditions should become available).
Statistical analysis. To test the reproducibility of our
quantitative techniques, we chose the sampling fields from 12
randomly selected biopsies of different transplant recipients
and determined interobserver and intraobserver variability.
The two investigators (C.V.L. and A.T.A.) who performed the
sample analyses for the entire study independently measured
in blinded fashion the 12 fields for both percent fibrosis and
myocyte diameter. The two investigators differed by a mean of
2.9% (representing 0.46% in absolute fibrosis) for fibrosis and
2.7% (representing 0.43 mm in absolute length) for myocyte
measurements. These two investigators then blindly analyzed
the same 12 fields a week or more later to compare the values
with their original determinations. Investigator 1 (C.V.L.)
differed by 5.4% (0.87% in absolute fibrosis) and 1.5%
(0.23 mm in absolute length) from his first set of fibrosis and
myocyte measurements while investigator 2 (A.T.A.) differed
by 5.2% (0.75% in absolute fibrosis) and 3.3% (0.55 mm in
absolute length) from his original set.
Statistical analyses of the data were performed under the
guidance and consultation of the Biometrics Laboratory of the
School of Public Health of The Ohio State University (Dr. Mel
Moeschberger, director). One way analysis of variance
(ANOVA) was used to statistically compare interstitial fibrosis
and myocyte diameter among the three patient populations.
Repeated measures ANOVA with posttesting was employed to
determine whether numerical change in the mean values for
percent fibrosis and myocyte diameter over time within the
transplant group was statistically significant. Regression anal-
yses were applied to determine whether the posttransplant
data (percent fibrosis and myocyte diameter) were associated
with various potential provocative factors; factors which
achieved a p , 0.10 by univariate analysis were then tested by
multivariate analysis. All data are presented as mean 6 1 SD
and a statistically significant difference in mean values required
a p , 0.05.
Results
Myocyte diameter. The mean myocyte diameters of the
myocardial biopsies analyzed at each time point posttransplant
and for the normal and cardiomyopathy control groups are
presented in Figure 2. Based on the assumption that early
myocyte enlargement may be related to the effects of the
donor’s clinical condition, myocardial edema, harvest ischemia
and other factors, the biopsies taken at 6 months posttrans-
plant showed the smallest mean myocyte diameter and were
therefore used as the baseline for comparison with subsequent
time points. Relative to this consideration, the earliest post-
transplant biopsies (1 month) had mean myocyte diameters
that were numerically and almost statistically (p 5 0.0523)
larger than those of the 6-month samples. Repeated measures
ANOVA indicated a statistically significant increase in mean
cardiomyocyte diameter over time following the 6-month
baseline nadir. For individual mean values at various time
points, post-ANOVA testing showed that a statistical increase
in myocyte diameter occurred at 2 years (p , 0.01) and
remained so at all subsequent time points. After transplant, the
mean myocyte diameter steadily increased as shown in Figure
2 and verified by interpoint statistical analysis (e.g., the in-
crease from 12 to 36 months posttransplant achieved a p ,
0.0001).
The mean myocyte diameter of the allograft baseline (6
months) was not significantly different from that of the normal
control group. However, the allograft myocyte diameters at 1
year posttransplant and beyond were all statistically larger than
the mean myocyte diameter of the normal controls. The mean
myocyte diameter of the dilated cardiomyopathy group was
significantly larger than that of the normal controls and larger
Figure 2. Mean (6 1 SD) cardiomyocyte diameters at serial time
points after cardiac transplantation in 50 patients up to 60 months and
30 patients at 72 months. Data from 40 dilated cardiomyopathy
(DCM) patients and 11 normal control subjects were obtained for
comparison. *p , 0.05 vs. normal control; †p , 0.05 vs. DCM; ‡p ,
0.05 vs. baseline (6 months after transplant).
706 ARMSTRONG ET AL. JACC Vol. 32, No. 3
POSTTRANSPLANT MYOCARDIAL HISTOLOGY September 1998:704–10
than all of the allograft mean diameters throughout the 6 year
posttransplant course.
Interstitial fibrosis. The mean percent fibrosis of the biop-
sies taken from the posttransplant, normal control and dilated
cardiomyopathy groups are presented in Figure 3. After trans-
plant, the lowest mean percent fibrosis was noted at 1 month, and
this time point was therefore used as the allograft fibrosis baseline
for statistical comparisons. Although mean percent fibrosis in-
creased numerically by 1 month (1- vs. 2-month values) and
numerically remained above the baseline mean value throughout
the posttransplant period (p 5 0.06 by repeated measures
ANOVA), only the biopsies at 9 months and 1, 2, 3 and 5 years
posttransplant showed an amount of fibrosis which was statisti-
cally greater than baseline (each ,0.05 with post-ANOVA test-
ing). The mean change in percent fibrosis did not increase
progressively over time after transplantation; at 2 months and
beyond, the posttransplant mean values for percent fibrosis did
not differ statistically from each other.
Although percent fibrosis over time tended to remain
modestly elevated above the 1-month baseline for the trans-
planted patients, mean percent fibrosis at all time points $2
months posttransplant was statistically greater than that of the
normal controls and at various time points $9 months after
transplant tended to be greater than that observed for the
dilated cardiomyopathy group (Fig. 3).
Potential Provocative Factors for
Cardiomyocyte Hypertrophy and
Myocardial Fibrosis
Donor hearts. The heart donors consisted of 47 men and 3
women with a mean age of 25 6 8 years (range 11 to 48). The
mean donor body weight was 75.7 6 12.5 kg (range 53 to 109).
There was no direct relationship between donor body weight
and percent fibrosis or myocyte diameter. However, disparate
donor-recipient body weights may have influenced myocyte
cell diameter, although not at p , 0.05. Respective changes in
myocyte diameter from baseline to 2 years for donor body
weights 10 kg . recipient or mean donor/recipient weight
ratios of 1.30 6 0.20 (range 1.11 to 1.95) (n 5 16), within 10 kg
of recipient weight or mean donor/recipient weight ratios of
1.01 6 0.06 (range 0.90 to 1.10) (n 5 26) and for recipient
weights 10 kg . donor or mean donor/recipient weight ratios
of 0.80 6 0.07 (range 0.65 to 0.89) (n 5 8) were 1.41, 1.89 and
4.69 m (p 5 0.16) and from baseline to 5 years were 2.65, 2.73
and 5.42 microns (p 5 0.18). No consistent changes were noted
over time for mean percent fibrosis relative to donor-recipient
body weights or ratios.
The ischemic time of the donor heart averaged 140 6
54 min (range 42 to 340). Biopsies from both early (before
6 months) and later periods (after 6 months) after trans-
plantation were analyzed relative to donor ischemic times;
no correlations were found between ischemic time and the
amount of myocardial fibrosis or myocyte diameter.
Medications. The transplanted patients were taking vary-
ing amounts of standard immunosuppression medication,
namely cyclosporine, azathiaprine and prednisone. The respec-
tive daily mean doses of cyclosporine, azathiaprine and pred-
nisone given at the 5-year posttransplant point were 4.24 6
1.81 mg/kg (range 2.02 to 8.21), 122 6 57 mg (range 25 to 225)
and 10 6 6 mg (range 5 to 20). For control of systemic
hypertension over the 5- to 6-year follow-up period, 76% took
a diuretic daily for a minimum of 3 years, 56% a calcium-
channel blocking agent, 52% an angiotensin-converting en-
zyme inhibitor, 32% a beta-adrenergic blocker and/or another
agent in 22%. No relationships were clearly demonstrable
between immunosuppressive drug, antihypertensive agent or
dose for either and myocardial fibrosis or myocyte diameter;
with respect to cyclosporine, this applies to dose at each biopsy,
cumulative dose and blood level.
Posttransplant clinical conditions. Other potential con-
tributory factors for myocardial histologic change following
transplantation, including systemic hypertension, cardiac allo-
graft vasculopathy and cellular rejection, are shown in Table 1.
Systemic hypertension was defined as an outpatient blood
pressure recording .140/90 mm Hg. Cardiac allograft vascu-
lopathy was declared when the annual quantitated coronary
angiograms and/or intracoronary ultrasound studies showed
epicardial coronary lesions with .50% diameter narrowing or
distal coronary artery attenuation. Rejection was defined as
grade II, grade III or grade IV at any time during the given
year. Each of these factors was analyzed separately (univariate
and then multivariate analysis when applicable) with respect to
changes in fibrosis and myocyte diameter. No statistically
significant relationships were found between the presence or
absence of hypertension, coronary vasculopathy or rejection
and interstitial fibrosis or cardiomyocyte diameter. However,
there was a trend (p 5 0.103) for an increase in myocyte
diameter from baseline to 5 years posttransplant in the 11
patients with coronary vasculopathy (4.75 6 4.34 mm) vs. those
without angiographic vasculopathy (2.67 6 3.58).
Figure 3. Mean (6 1 SD) percent fibrosis of endomyocardial biopsy
specimens obtained serially after cardiac transplantation (n 5 50 at 60
months and n 5 30 at 72 months) and from 40 patients with primary
dilated cardiomyopathy (DCM) and 11 normal control subjects. *p ,
0.05 vs. normal control; †p , 0.05 vs. DCM; ‡p , 0.05 vs. baseline (1
month after transplant).
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Discussion
The hypothesis that cardiomyocyte diameter and myocar-
dial fibrosis increase progressively throughout the posttrans-
plant period is supported only in part by the results of this
investigation. Cardiomyocyte diameter gradually increased
from 6 months to 6 years after transplant. In contrast, inter-
stitial fibrosis rose within 2 months after transplant with little
additional change over the subsequent 5 to 6 years.
Myocyte diameter. The current data correspond well with
those of a previous report (2) analyzing cardiomyocyte diam-
eter at a single time point 3 years after transplantation;
specifically, a mean value of 20.3 6 3.0 mm was reported
compared with 18.4 6 3.4 mm of the current study. The authors
are not aware that comparable histologic data of biopsies are
available elsewhere for sequential time points posttransplant.
While determining the posttransplant provocative factors
for myocyte enlargement and myocardial fibrosis was not a
primary objective of this study, we found, similar to previous
reports (1–3,14), little to no correlation between cardiomyo-
cyte diameter and donor body size, immunosuppressive agent
or dose, donor ischemic time or the number of rejection
episodes. Albeit not statistically significant, change in myocyte
diameter tended to vary inversely with the donor/recipient
body weight ratio; this complements the report by Mather et al.
(15) showing that undersized hearts usually enlarge to meet
the needs of the recipient. In addition, the data of our
investigation suggest that substantial coronary allograft vascu-
lopathy may serve as a stimulus for posttransplant cardiomyo-
cyte enlargement, but at a p 5 0.103 level. Although there was
no obvious statistical relationship between cardiomyocyte di-
ameter and posttransplant blood pressure, the high prevalence
of blood pressure recordings above 140/90 mm Hg posttrans-
plant is rather striking (Table 1), a finding consistent with
blood pressure patterns reported for most other posttransplant
populations (5–9,11). In contrast to normal populations and
the normal control group of this study, the blood pressure of
posttransplant patients is infrequently ,130/80 mm Hg. Ele-
vation in systemic blood pressure, as well as the ventricular-
vascular uncoupling which results in impedance mismatch
between the transplanted denervated ventricle and recipient
aorta-vasculature, likely serve as stimuli to cardiomyocyte
enlargement. It is difficult to exclude a direct effect of immu-
nosuppressive medications; these agents, particularly cyclo-
sporine and corticosterioids, at least contribute indirectly by
evoking a large part of the systemic hypertension noted
posttransplant.
The mean cardiomyocyte diameter of the dilated cardiomy-
opathy group, comparable to that previously reported from
this laboratory using a manual method (13), was still larger
than all of the mean myocyte diameters along the entire 6-year
course of the posttransplant hearts. This difference may in part
be attributable to the rather high ventricular wall stress and
numerous other physical, neurogenic and hormonal stimuli in
the patient with dilated cardiomyopathy.
As far as the authors are aware, the reduction in cell widthTa
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over the first 6 months posttransplant is a new observation.
Data are not available in this report to define a mechanism.
Cellular recovery and repair and reestablishment of microvas-
cular blood flow over the first few months posttransplant are
reasonable considerations.
Interstitial fibrosis. The extent of myocardial fibrosis (15%
to 19%) posttransplant in the current study is somewhat higher
than the myocardial collagen fraction (4% to 10%) previously
reported (2,3,14). This disparity is likely related to differences
in analytical techniques in that the methodology of the current
study measures total fibrosis irrespective of its components and
it eliminates nonmyocardial space (e.g., sizable vasculature,
clear nontissue spaces) to provide a corrected value for total
myocardium. The mean percent fibrosis of the current dilated
cardiomyopathy group is comparable to that of the dilated
cardiomyopathy patients previously reported from this labora-
tory using a manual, grid point-counting technique (13).
Percent fibrosis increased within 2 months posttransplant, a
finding also noted by Pickering and Boughner (3). Rather than
representing a pathophysiologic process, it is possible that
percent fibrosis rose simply because cardiomyocyte diameter
decreased during this time period, allowing more fibrous tissue
to occupy the sampling field.
After the initial rise in percent fibrosis, there was little
additional increase over the subsequent 6-year posttransplant
period. Another study using a mouse cardiac allograft model
supports this finding by showing an increase in percent fibrosis
in transplanted hearts that was immediate and did not progres-
sively increase over time (16). This, of course, does not mean
that total cardiac fibrosis does not increase with time posttrans-
plant. In fact, no change in percent fibrosis indicates that total
cardiac fibrous tissue must increase in proportion to the usual
increase in cardiac weight and ventricular wall thickness. The
current study does not elucidate a distinct fibrosis-inducing
factor or mechanism. That proportional fibrous deposition
accompanies the myocardial and cellular hypertrophic process
is a reasonable view. On the other hand, the development of
interstitial fibrosis may be largely independent of myocyte
growth with differing responses in fibrosis type, extent and
manifestations in individual patients with different predispos-
ing factors (17).
Limitations of the study. As in all retrospective studies, the
investigators were not able to rigidly control variables such as
medications, doses and blood pressure, nor can the trans-
planted group be properly or adequately matched with other
posttransplant groups to control for relevant independent
variables. Patients who expired before arriving at the 5-year
posttransplant study point were not included; their data may
have modified the data of this report. For the normal control
group, the investigators cannot guarantee that the neoplastic
condition did not affect the cardiomyocyte diameter or percent
fibrosis of the individual. Biopsies were taken only from the
right side of the interventricular system and some of the factors
studied might primarily affect the left ventricle (e.g., systemic
hypertension, coronary vasculopathy); however, studies from
this laboratory indicate that histopathologic changes seen in
right ventricular-septal specimens parallel those noted along
the left side of the septum and the left ventricular free wall and
are directly influenced by left heart events and interventions
(13,18). The methodology employed measured only cardiomy-
ocyte diameter and not total cardiomyocyte area or volume.
The change in width may not indicate a change in other
cellular dimensions. The reader may refer to Methods for
additional methodological considerations.
We conclude that there is a progressive increase in cardio-
myocyte diameter in heart transplant patients up to 6 years
posttransplant. A nonprogressive fibrotic response also occurs
in the transplanted heart, perhaps as early as 1 to 2 months
posttransplant. The structural changes likely affect short- and
long-term cardiac function and possibly complicate the post-
transplant course. These data provide the basis for future
studies exploring the mechanisms for the observed myocyte
hypertrophy and myocardial fibrosis after transplantation.
The authors thank Gretchen Whitby, RN, CCTC, for collecting vast amounts of
clinical data and Ms. Deborah Black for preparing the manuscript.
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